|
Aiko's patented portfolio of compounds includes naltrexone / naloxone analogs, including naltrexol, naltrexamine and naloxol derivatives. Each compound has been demonstrated to display neutral antagonist properties at the mu opioid receptor.
| |
AIKO Biotechnology, Inc.
2 Union Street
Suite 501
Portland, ME 04101
Victor Otley, Chairman
votley@aikobiotech.com
Cell: 207-329-6093
Bill Emhiser, President
bemhiser@aikobiotech.com
Cell: 978-821-0602
Janet Yancey-Wrona, Chief Operating Officer
jyancey@aikobiotech.com
Cell: 207-317-0960
|
